Greenland Mines Ltd (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders.
This patent grant represents a significant milestone for Greenland Mines, as it bolsters the company’s intellectual property portfolio in the growing field of gene therapy. The Klotho protein, often referred to as the “longevity protein,” has been studied for its potential neuroprotective and anti-aging effects. By securing patent protection in Australia, Greenland Mines extends its IP coverage beyond the United States and other jurisdictions, potentially increasing the value of its therapeutic platform. The patent covers key components of the gene therapy approach, including constructs, stem cells, and delivery systems, which are critical for developing effective treatments.
The KLTO-202 program is focused on ALS, a devastating neurodegenerative disease with limited treatment options. ALS affects motor neurons, leading to progressive muscle weakness and paralysis. The approval of this patent could accelerate development of KLTO-202 by providing additional exclusivity in the Australian market. For patients and the medical community, this news signals continued progress toward potential new therapies. For investors, the strengthened IP position may enhance the company’s valuation and partnership opportunities.
Greenland Mines operates through two divisions: Mining and Biotech. The Mining division focuses on the Skaergaard Project in southeast Greenland and the Sarfartoq rare earths project in southwest Greenland. The Biotech division is advancing the Klotho platform, with KLTO-202 as its primary indication. The company’s strategy includes building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and midstream processing, while supporting its broader North Atlantic Critical Metals Corridor vision. The full press release is available at https://nnw.fm/PVbbH.
This patent news underscores the importance of intellectual property in the biotech sector. For Greenland Mines, it provides a competitive edge in the development of gene therapies for neuromuscular diseases. The implications for the industry are notable, as Klotho-based therapies could open new avenues for treating conditions like ALS. For the world, this represents a step forward in addressing unmet medical needs. As the company advances its KLTO-202 program, stakeholders will be watching for further clinical developments and regulatory milestones.
